JP2008508903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508903A5 JP2008508903A5 JP2007526144A JP2007526144A JP2008508903A5 JP 2008508903 A5 JP2008508903 A5 JP 2008508903A5 JP 2007526144 A JP2007526144 A JP 2007526144A JP 2007526144 A JP2007526144 A JP 2007526144A JP 2008508903 A5 JP2008508903 A5 JP 2008508903A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- protein
- complementarity determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 38
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 36
- 102000004169 proteins and genes Human genes 0.000 claims 25
- 108090000623 proteins and genes Proteins 0.000 claims 25
- 108091008324 binding proteins Proteins 0.000 claims 16
- 102000023732 binding proteins Human genes 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 229940127121 immunoconjugate Drugs 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 238000012360 testing method Methods 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 5
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 239000003053 toxin Substances 0.000 claims 5
- 231100000765 toxin Toxicity 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102100032912 CD44 antigen Human genes 0.000 claims 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000012830 cancer therapeutic Substances 0.000 claims 3
- -1 carrier Substances 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- 238000012875 competitive assay Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 claims 1
- 108010084592 Saporins Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 108010049223 bryodin Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 229940051026 immunotoxin Drugs 0.000 claims 1
- 239000002596 immunotoxin Substances 0.000 claims 1
- 231100000608 immunotoxin Toxicity 0.000 claims 1
- 230000002637 immunotoxin Effects 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57829104P | 2004-06-10 | 2004-06-10 | |
| US60/578,291 | 2004-06-10 | ||
| PCT/CA2005/000899 WO2005121341A1 (en) | 2004-06-10 | 2005-06-10 | Tumor specific antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012078467A Division JP2012187104A (ja) | 2004-06-10 | 2012-03-30 | 腫瘍特異的抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008508903A JP2008508903A (ja) | 2008-03-27 |
| JP2008508903A5 true JP2008508903A5 (OSRAM) | 2008-07-24 |
| JP5026268B2 JP5026268B2 (ja) | 2012-09-12 |
Family
ID=35503067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526144A Expired - Fee Related JP5026268B2 (ja) | 2004-06-10 | 2005-06-10 | 腫瘍特異的抗体 |
| JP2012078467A Pending JP2012187104A (ja) | 2004-06-10 | 2012-03-30 | 腫瘍特異的抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012078467A Pending JP2012187104A (ja) | 2004-06-10 | 2012-03-30 | 腫瘍特異的抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8383117B2 (OSRAM) |
| EP (2) | EP2927322A1 (OSRAM) |
| JP (2) | JP5026268B2 (OSRAM) |
| CN (1) | CN101044242B (OSRAM) |
| AU (1) | AU2005252275B2 (OSRAM) |
| CA (1) | CA2569788C (OSRAM) |
| ES (1) | ES2535229T3 (OSRAM) |
| IL (1) | IL179891A (OSRAM) |
| NZ (1) | NZ552476A (OSRAM) |
| PL (1) | PL1766017T3 (OSRAM) |
| WO (1) | WO2005121341A1 (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2826735C (en) | 2003-04-30 | 2019-06-04 | University Of Zurich | Methods for treating cancer using an immunotoxin |
| DK1737961T3 (da) | 2004-03-19 | 2013-08-05 | Merck Patent Gmbh | Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf |
| CA2633138A1 (en) | 2005-12-23 | 2007-06-28 | Viventia Biotech Inc. | Methods for generating and screening fusion protein libraries and uses thereof |
| CA2684330A1 (en) | 2007-04-19 | 2008-10-30 | Viventia Biotech Inc. | Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins |
| GB0718045D0 (en) | 2007-09-14 | 2007-10-24 | Peptcell Ltd | Pharmaceutical compound |
| WO2009039630A1 (en) | 2007-09-27 | 2009-04-02 | Viventia Biotech Inc. | Optimized nucleic acid sequences for the expression of vb4-845 |
| JP2011509244A (ja) * | 2007-12-21 | 2011-03-24 | ユニバーシティー オブ ロチェスター | 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４ |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| TWI404931B (zh) * | 2009-02-20 | 2013-08-11 | Nat Synchrotron Radiation Res Ct | 癌化生物樣本之檢測方法及其使用之檢驗試劑 |
| JP6041333B2 (ja) * | 2011-01-13 | 2016-12-07 | 学校法人近畿大学 | 抗腫瘍剤 |
| EP3729958B1 (en) * | 2013-03-15 | 2023-05-03 | Mayo Foundation for Medical Education and Research | Identification and monitoring of monoclonal immunoglobulins by molecular mass |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| DK3052525T3 (da) | 2013-10-02 | 2019-10-07 | Viventia Bio Inc | Anti-epcam-antistoffer og anvendelsesfremgangsmåder |
| CA2944767C (en) | 2014-04-04 | 2022-07-12 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| EP3175242A4 (en) | 2014-07-29 | 2017-12-27 | Mayo Foundation for Medical Education and Research | Quantifying monoclonal antibody therapeutics by lc-ms/ms |
| WO2016068294A1 (ja) * | 2014-10-31 | 2016-05-06 | 株式会社カネカ | タンパク質合成阻害タンパク質毒素を含むポリペプチドの製造方法 |
| AU2016228760B2 (en) | 2015-03-12 | 2020-07-16 | Viventia Bio Inc. | Dosing strategies for targeting EPCAM positive bladder cancer |
| JP6824183B2 (ja) | 2015-03-12 | 2021-02-03 | セセン バイオ，インコーポレイテッド | Ｅｐｃａｍ陽性膀胱癌の処置方法 |
| WO2016187571A2 (en) * | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Her2 immunotoxins and methods of using the same |
| RU2765574C2 (ru) | 2015-08-12 | 2022-02-01 | Онкотерапи Сайенс, Инк. | Пептид, полученный из depdc1, и содержащая его вакцина |
| US11209439B2 (en) | 2015-09-24 | 2021-12-28 | Mayo Foundation For Medical Education And Research | Identification of immunoglobulin free light chains by mass spectrometry |
| CN105510586B (zh) * | 2015-12-22 | 2017-09-12 | 湖北鹊景生物医学有限公司 | 用于肺癌诊断的试剂盒及其使用方法 |
| US10955420B2 (en) | 2016-09-07 | 2021-03-23 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| WO2019055632A1 (en) | 2017-09-13 | 2019-03-21 | Mayo Foundation For Medical Education And Research | IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J |
| EP3681528B1 (en) | 2017-09-13 | 2025-07-23 | Mayo Foundation for Medical Education and Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| CN109324189B (zh) * | 2018-08-15 | 2021-10-01 | 泰达国际心血管病医院 | 多蛋白组合物的应用及先天性心脏病筛查试剂盒 |
| CN111138521B (zh) * | 2018-11-06 | 2022-10-28 | 香雪生命科学技术（广东）有限公司 | 源自于afp抗原的短肽 |
| CN114040774A (zh) * | 2019-02-15 | 2022-02-11 | 阿特雷卡公司 | 结合肿瘤组织用于诊断和治疗的抗体 |
| CN112300261B (zh) * | 2019-07-23 | 2023-03-17 | 香雪生命科学技术（广东）有限公司 | 一种衍生自afp的肿瘤抗原短肽 |
| CN112851811B (zh) * | 2021-01-28 | 2022-08-09 | 姜国胜 | 一种cd44v6纳米抗体及其作为白血病研究试剂的应用 |
| CN114773478B (zh) * | 2022-03-14 | 2023-05-23 | 深圳市国创纳米抗体技术有限公司 | 抗afp抗原vhh结构域及含有其的双特异性抗体 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116297727B (zh) * | 2022-09-13 | 2024-01-23 | 山东大学齐鲁医院 | 一种甲胎蛋白和异常凝血酶原电致发光传感器的制备及其应用 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| CN1042940A (zh) * | 1988-12-01 | 1990-06-13 | 中国农业科学院哈尔滨兽医研究所 | 马传贫病马与接种弱毒疫苗马的血清抗体鉴别诊断试剂 |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| US5863540A (en) * | 1991-03-15 | 1999-01-26 | Duke University | Adhesion molecule |
| CN1075208A (zh) * | 1992-12-02 | 1993-08-11 | 张昌卿 | 一种检测eb病毒抗体的显色试剂及其制造方法 |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| JP2003299497A (ja) * | 2002-02-05 | 2003-10-21 | Masayoshi Kachi | ムコ多糖類及びその製造方法 |
| WO2003066830A2 (en) * | 2002-02-08 | 2003-08-14 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
| TW201319088A (zh) * | 2003-07-18 | 2013-05-16 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
| DK1737961T3 (da) | 2004-03-19 | 2013-08-05 | Merck Patent Gmbh | Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf |
| US8802442B2 (en) | 2011-11-30 | 2014-08-12 | Eric B. Wheeldon | Apparatus and method for the remote sensing of blood in human feces and urine |
-
2005
- 2005-06-10 NZ NZ552476A patent/NZ552476A/en not_active IP Right Cessation
- 2005-06-10 JP JP2007526144A patent/JP5026268B2/ja not_active Expired - Fee Related
- 2005-06-10 US US11/570,198 patent/US8383117B2/en not_active Expired - Fee Related
- 2005-06-10 PL PL05754865T patent/PL1766017T3/pl unknown
- 2005-06-10 CA CA2569788A patent/CA2569788C/en not_active Expired - Fee Related
- 2005-06-10 AU AU2005252275A patent/AU2005252275B2/en not_active Ceased
- 2005-06-10 EP EP14198378.3A patent/EP2927322A1/en not_active Withdrawn
- 2005-06-10 CN CN2005800272005A patent/CN101044242B/zh not_active Expired - Fee Related
- 2005-06-10 WO PCT/CA2005/000899 patent/WO2005121341A1/en not_active Ceased
- 2005-06-10 ES ES05754865.3T patent/ES2535229T3/es not_active Expired - Lifetime
- 2005-06-10 EP EP05754865.3A patent/EP1766017B1/en not_active Expired - Lifetime
-
2006
- 2006-12-06 IL IL179891A patent/IL179891A/en not_active IP Right Cessation
-
2012
- 2012-03-30 JP JP2012078467A patent/JP2012187104A/ja active Pending
-
2013
- 2013-01-17 US US13/743,672 patent/US8969540B2/en not_active Expired - Lifetime
-
2015
- 2015-01-23 US US14/604,047 patent/US20150197575A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508903A5 (OSRAM) | ||
| US10494435B2 (en) | Human monoclonal antibodies specific for CD22 | |
| CN105026429B (zh) | 间皮素结构域-特异性单克隆抗体及其用途 | |
| JP2011501946A5 (OSRAM) | ||
| US12037404B2 (en) | Human monoclonal antibodies against EphA4 and their use | |
| CN112533633A (zh) | Cd4的抗原结合构建体 | |
| TW202146456A (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| JP2005518789A5 (OSRAM) | ||
| JP2008538289A5 (OSRAM) | ||
| JP2012525432A5 (OSRAM) | ||
| JP2011525354A5 (OSRAM) | ||
| JP6612324B2 (ja) | αＫｌｏｔｈｏに対して高親和性を有する抗体 | |
| JP2019506140A5 (OSRAM) | ||
| JP7743406B2 (ja) | 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法 | |
| CN119013305A (zh) | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 | |
| CN116249547A (zh) | 脑特异性血管生成抑制剂1(bai1)抗体及其用途 | |
| CN119343378A (zh) | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 | |
| JP2008523825A5 (OSRAM) | ||
| CN101432308A (zh) | Fas结合抗体 | |
| US11377504B2 (en) | Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same | |
| JP2020533955A5 (OSRAM) | ||
| WO2017055511A1 (en) | Compositions and methods for inhibiting cancer stem cells | |
| US20200190480A1 (en) | ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING | |
| WO2013059206A2 (en) | Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii) | |
| WO2025112030A1 (zh) | B7h3结合多肽及其用途 |